Breast Cancer

Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Anees B. Chagpar, MD, outlines several strategies to minimize the use of ALND in patients with breast cancer.

Enrique Soto Pérez de Celis, MD, MSc, discusses some of the challenges of treating geriatric patients with breast cancer, emerging treatment options for this patient population, and recommendations for treating older patients.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

Richa Dawar, MD, discusses challenges with the use of neratinib in patients with metastatic HER2-positive breast cancer.

Maxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.

During a recent OncLive Peer Exchange®, the expert panel focused on the development of immunotherapy and other notable successes based on recent presentations at the 2019 San Antonio Breast Cancer Symposium.